Clareo Health | Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)
Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Gilead Sciences
With
GOG Foundation
European Network of Gynaecological Oncological Trial Groups (ENGOT)
Asia-Pacific Gynecologic Oncology Trials Group
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Documented evidence of recurrent/persistent endometrial cancer (endometrial carcinoma or carcinosarcoma).
Up to 3 prior lines of systemic therapy for endometrial cancer, including systemic platinum-based chemotherapy and anti-PD-1/PD-L1 therapy, either in combination or separately.
Eligible for treatment with either doxorubicin or paclitaxel as determined by the investigator.
Radiologically evaluable disease (either measurable or nonmeasurable) by computed tomography (CT) or magnetic resonance imaging (MRI) per RECIST v1.1.
Eastern Cooperative Oncology Group performance status score of 0 or 1.
Adequate organ function
You may not be if
Uterine leiomyosarcoma and endometrial stromal sarcomas are excluded.
Participants who are candidates for curative-intent therapy at the time of study enrollment.
Participants eligible for rechallenge with platinum-based chemotherapy as determined by the investigator.
Received any prior treatment with a Trop-2-directed antibody-drug conjugate (ADC).
Have an active second malignancy.
Have an active serious infection requiring systemic antimicrobial therapy.
Have active chronic inflammatory bowel disease (ulcerative colitis, Crohn's disease) or gastrointestinal perforation within 6 months prior to randomization.
Have a positive serum pregnancy test or are breastfeeding for participants who are assigned female at birth.
